AWA
CCCC icon

Arete Wealth Advisors’s C4 Therapeutics CCCC Stock Holding History

Arete Wealth Advisors’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-73,350
Closed -$418K – 751
2024
Q3 		$418K Sell
73,350
-37,950
-34% -$228K 0.04% 417
2024
Q2 		$514K Buy
111,300
+26,100
+31% +$156K 0.04% 384
2024
Q1 		$696K Buy
85,200
+13,100
+18% +$102K 0.06% 262
2023
Q4 		$407K Buy
+72,100
New +$164K 0.03% 463

Other funds holding CCCC

SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Arete Wealth Advisors's CCCC Position: Q4 2024 in Review

Arete Wealth Advisors sold out of C4 Therapeutics (CCCC) in Q4 2024, closing a stake of 73,350 shares — an estimated $418K sold.

Arete Wealth Advisors first reported a position in CCCC in Q4 2023 and held it in 4 quarters. The position peaked at $696K in Q1 2024. 113 funds tracked by Wall St. Rank hold CCCC as of Q4 2024.

  • Arete Wealth Advisors reported no remaining C4 Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Arete Wealth Advisors sold 73,350 C4 Therapeutics shares in Q4 2024, an estimated $418K.
  • Arete Wealth Advisors first reported a position in C4 Therapeutics in Q4 2023 and held it in 4 quarters.
  • Arete Wealth Advisors's C4 Therapeutics position peaked at $696K in Q1 2024.
  • 113 funds tracked by Wall St. Rank held C4 Therapeutics as of Q4 2024.

Based on Arete Wealth Advisors's 13F filing for Q4 2024, filed 12 Feb 2025.